Otonomy to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company focused on innovative neurotology therapeutics, will participate in two virtual conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a pre-recorded fireside chat available on-demand from September 13, 2021, at 7 a.m. ET. The Cantor Global Healthcare Conference will have a live presentation on September 29, 2021, at 2:40 p.m. ET. Both presentations will be accessible via the Events page on Otonomy's website.

News Market Reaction – OTIC

+1.96%

+1.96% Session move

In the trading session that priced this news, OTIC gained 1.96%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in two upcoming virtual conferences:

• H.C. Wainwright 23rd Annual Global Investment Conference: a pre-recorded fireside chat will be available on-demand starting at 7 a.m. ET / 4 a.m. PT on September 13, 2021;
  
• Cantor Global Healthcare Conference: presentation on September 29, 2021 at 2:40 p.m. ET / 11:40 a.m. PT.
  

The pre-recorded H.C. Wainwright presentation and the live audio webcast and archived replay of the Cantor presentation will be available through the Events page of the company's website (www.otonomy.com).

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

What is the date of Otonomy's participation in the H.C. Wainwright conference?

Otonomy will participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

When will the Cantor Global Healthcare Conference presentation take place for Otonomy?

The Cantor Global Healthcare Conference presentation will occur on September 29, 2021, at 2:40 p.m. ET.

Where can I watch the Otonomy conference presentations?

The presentations will be available on the Events page of Otonomy's website.

What is the focus of Otonomy as a biopharmaceutical company?

Otonomy is focused on developing innovative therapeutics for neurotology, particularly addressing hearing loss and tinnitus.

What innovative technology does Otonomy utilize in its drug development?

Otonomy uses drug delivery technology for the ear to achieve sustained drug exposure from a single local administration.